LXRX
Price
$0.70
Change
+$0.03 (+4.48%)
Updated
Apr 24 closing price
Capitalization
255.46M
6 days until earnings call
PLX
Price
$2.94
Change
-$0.02 (-0.68%)
Updated
Apr 24 closing price
Capitalization
229.42M
14 days until earnings call
Ad is loading...

LXRX vs PLX

Header iconLXRX vs PLX Comparison
Open Charts LXRX vs PLXBanner chart's image
Lexicon Pharmaceuticals
Price$0.70
Change+$0.03 (+4.48%)
Volume$7.29M
Capitalization255.46M
Protalix BioTherapeutics
Price$2.94
Change-$0.02 (-0.68%)
Volume$1.49M
Capitalization229.42M
LXRX vs PLX Comparison Chart
Loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LXRX vs. PLX commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a Buy and PLX is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (LXRX: $0.70 vs. PLX: $2.94)
Brand notoriety: LXRX and PLX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 38% vs. PLX: 205%
Market capitalization -- LXRX: $255.46M vs. PLX: $229.42M
LXRX [@Biotechnology] is valued at $255.46M. PLX’s [@Biotechnology] market capitalization is $229.42M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.16B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 1 FA rating(s) are green whilePLX’s FA Score has 1 green FA rating(s).

  • LXRX’s FA Score: 1 green, 4 red.
  • PLX’s FA Score: 1 green, 4 red.
According to our system of comparison, LXRX is a better buy in the long-term than PLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXRX’s TA Score shows that 6 TA indicator(s) are bullish while PLX’s TA Score has 6 bullish TA indicator(s).

  • LXRX’s TA Score: 6 bullish, 4 bearish.
  • PLX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, both LXRX and PLX are a good buy in the short-term.

Price Growth

LXRX (@Biotechnology) experienced а +37.98% price change this week, while PLX (@Biotechnology) price change was +12.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

LXRX is expected to report earnings on Jul 31, 2025.

PLX is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LXRX($255M) has a higher market cap than PLX($229M). PLX YTD gains are higher at: 56.383 vs. LXRX (-4.753). PLX has higher annual earnings (EBITDA): -6.48M vs. LXRX (-184.29M). LXRX has more cash in the bank: 238M vs. PLX (27.4M). PLX has less debt than LXRX: PLX (5.68M) vs LXRX (108M). PLX has higher revenues than LXRX: PLX (45.7M) vs LXRX (31.1M).
LXRXPLXLXRX / PLX
Capitalization255M229M111%
EBITDA-184.29M-6.48M2,846%
Gain YTD-4.75356.383-8%
P/E RatioN/A73.50-
Revenue31.1M45.7M68%
Total Cash238M27.4M869%
Total Debt108M5.68M1,900%
FUNDAMENTALS RATINGS
LXRX vs PLX: Fundamental Ratings
LXRX
PLX
OUTLOOK RATING
1..100
3421
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
81
Overvalued
PROFIT vs RISK RATING
1..100
10087
SMR RATING
1..100
9793
PRICE GROWTH RATING
1..100
4235
P/E GROWTH RATING
1..100
182
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LXRX's Valuation (58) in the Biotechnology industry is in the same range as PLX (81) in the Servicestothe Health Industry industry. This means that LXRX’s stock grew similarly to PLX’s over the last 12 months.

PLX's Profit vs Risk Rating (87) in the Servicestothe Health Industry industry is in the same range as LXRX (100) in the Biotechnology industry. This means that PLX’s stock grew similarly to LXRX’s over the last 12 months.

PLX's SMR Rating (93) in the Servicestothe Health Industry industry is in the same range as LXRX (97) in the Biotechnology industry. This means that PLX’s stock grew similarly to LXRX’s over the last 12 months.

PLX's Price Growth Rating (35) in the Servicestothe Health Industry industry is in the same range as LXRX (42) in the Biotechnology industry. This means that PLX’s stock grew similarly to LXRX’s over the last 12 months.

PLX's P/E Growth Rating (2) in the Servicestothe Health Industry industry is in the same range as LXRX (18) in the Biotechnology industry. This means that PLX’s stock grew similarly to LXRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LXRXPLX
RSI
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 5 days ago
87%
Bullish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 3 days ago
84%
Declines
ODDS (%)
Bearish Trend 10 days ago
87%
Bearish Trend 18 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
77%
View a ticker or compare two or three
Ad is loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PLX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
USERX16.170.29
+1.83%
US Global Investors Gld & Prec Mtls
DEMRX20.62N/A
N/A
Macquarie Emerging Markets R
NSFEX10.05N/A
N/A
Natixis Target Retirement 2025 N
BIIEX23.37N/A
N/A
Brandes International Equity I
REIGX14.82N/A
N/A
Federated Hermes International Growth R6

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with PLRX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then PLRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
+4.70%
PLRX - LXRX
42%
Loosely correlated
+1.95%
ABOS - LXRX
38%
Loosely correlated
+7.84%
VCYT - LXRX
37%
Loosely correlated
+2.15%
OCUL - LXRX
36%
Loosely correlated
+0.64%
RXRX - LXRX
36%
Loosely correlated
+3.05%
More

PLX and

Correlation & Price change

A.I.dvisor tells us that PLX and STOK have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PLX and STOK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PLX
1D Price
Change %
PLX100%
-0.68%
STOK - PLX
31%
Poorly correlated
+3.78%
ZNTL - PLX
31%
Poorly correlated
+0.67%
CPRX - PLX
31%
Poorly correlated
+0.30%
SNDX - PLX
31%
Poorly correlated
+2.31%
LXRX - PLX
31%
Poorly correlated
+4.70%
More